New drug combo shows early promise for recurrent lymphoma

NCT ID NCT01644799

Completed Disease control Sponsor: Alliance for Clinical Trials in Oncology Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested two drugs, lenalidomide and idelalisib, in 8 people with follicular lymphoma that had returned after previous treatment. Lenalidomide helps the immune system fight cancer, while idelalisib blocks enzymes that cancer cells need to grow. The main goal was to find the safest dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide and idelalisib
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with recurrent follicular lymphoma.
What could go wrong: This is a very early, small phase I trial with only 8 participants, so results may not apply broadly. The main goal is safety, not yet effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT FOLLICULAR LYMPHOMA

Contacts and locations

Locations

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
Ohio State University Medical Center

Columbus, Ohio, 43210, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Weill Medical College of Cornell University

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.